The European Commission has ordered the manufacturer of the type II diabetes medication Actos to issue a new warning about the drug in order to keep it on sale in Europe. The new warning will carry info about the risk of developing bladder cancer for patients who take Actos for more than one year.
After researchers found that Actos could increase a patient’s risk of bladder cancer by as much as 40%, the Food and Drug Administration issued a warning to consumers about the side effects of the drug. Health officials in France and Germany also suspended sales of Actos in response to the study.
Takeda is already facing several Actos lawsuits in North America alleging that the company failed to properly warn patients of the increased risk of bladder cancer associated with the drug. Attorneys involved in the cases predict as many as 10,000 bladder cancer lawsuits could be filed in the coming years.